Category Archives: Neurology

LIDBREE™ receives marketing authorization in the United Kingdom

SANTA BARBARA, CALIF., U.S.A. / BUDAPEST / STOCKHOLM, 5-Aug-2020 — /EPR HEALTHCARE NEWS/ — Palette Life Sciences AB (‘Palette’) with Gedeon Richter Plc. (‘Richter’), today announced that as a part of a decentralised regulatory procedure including thirty European Union Economic Area member states, Palette and Richter received national marketing authorization for LIDBREE™ in the United Kingdom (UK). The product is a novel, proprietary thermo gelling intrauterine formulation that can provide significant pain relief during common gynecological procedures.

LIDBREE’s marketing authorization is based on compelling data from clinical trials and investigations of sensory innervation in the reproductive area. In a pivotal clinical trial, LIDBREE treatment was associated with a significant reduction of pain and discomfort in women undergoing gynecological interventions.¹

“Our research group has detected pain nerves superficially throughout the uterus, which enable the use of local pain relief in many gynecological procedures such as insertion of an intrauterine device and sampling biopsies from the cervix and/or from the uterus – procedures that are currently routinely performed today without pain relief. LIDBREE is a novel gel containing the local anesthetic lidocaine which adheres to the mucosal tissue upon application to provide excellent analgesic effect”, says Gunvor Ekman-Ordeberg, MD PhD Professor at Karolinska Institute and founder of the LIDBREE program. “The gratification of observing the culmination of over 40 years of research into clinical practice via a new, simple, and effective treatment is a great privilege to share with all of my colleagues.”

In October 2017, Richter and Palette signed an agreement to commercialise LIDBREE, a novel innovative proprietary pain relief pharmaceutical formulation, in Europe and in certain other markets.

“We are very pleased with the approval of LIDBREE in the UK, it is a great accomplishment from everyone involved.  This is an important milestone and allows us to address a significant unmet medical need in women’s health. We look forward to supporting LIDBREE’s product launch through our partner Gedeon Richter and pursuing additional markets, such as the U.S., in collaboration with future regional partners.” says Helena Jansson, Managing Director at Palette Life Sciences AB.

“We’ve been expecting this regulatory development and we are looking forward to successfully introduce LIDBREE to all of the territories covered by our agreement in order to further improve the quality of life of women experiencing pain during their gynaecological interventions,” stated Tibor Horváth, Commercial Director of Gedeon Richter Plc.

SOURCE: EuropaWire

TESTmyBRAIN opens its first center of Functional Neurology in Europe

GENEVA, 2016-Jun-8 — /EPR Healthcare News/ — TESTmyBRAIN (Switzerland) has opened its first center of Functional Neurology in Europe. This non-invasive therapy (no medication, no surgery) coming from the United States helps patients suffering from migraines, concussions, strokes, AD/HD, Parkinson disease, Alzheimer, … all disorders related to the brain and the central nervous system.

This innovative therapy combines several approaches and relies mainly over 3 decades of research on the eye-movements to diagnose and treat. Completely adopted and established in the United States, this therapy is almost unknown in Europe.

This is the reason why TESTmyBRAIN Switzerland is happy to bring the American experts to Europe to teach other doctors and to help patients differently with their pain.

SOURCE: EuropaWire

The End of Alzheimer’s? A revolutionary scientific advance to the cure

Interface Dynamics Control Corporation (IDCC) has completed the first phase of its decade-long Advanced Therapeutic Interventions Project, with the result that a new approach to arresting and curing Alzheimer’s disease and the other neurodegenerative diseases has been produced and verified. IDCC is now launching the Project’s second phase, which will validate the first phase findings.

Alzheimer’s disease is the sixth leading cause of death in the United States, with more than 5.1 million Americans currently affected. The direct cost of Alzheimer’s is greater than $200 billion annually, a number expected reach between $1.2 and $1.5 trillion by 2050. Indirect costs are substantial: more than 15 million caregivers delivered some 17.5 billion hours of unpaid care valued at more than $200 billion.

IDCC has discovered the mechanism of and means to control the protein misfolding, abnormal aggregation, and degradation processes associated with the degenerative and prion diseases. That mechanism is also implicated in the failure to clear toxic intracellular proteins and in the dysfunction of apoptotic (programmed cell death) pathways. It underlies the adverse functions of the neuroglia (glial cells), including microglia, which provide immune defense to the central nervous system (CNS) and maintain homeostasis and protection for neurons in the brain and the peripheral nervous system.

The process of neurodegeneration has not been understood previously, which has precluded the production of any arresting or curative procedures or drugs. The Project’s findings, however, should lead to the realization of a new class of curative procedures and pharmaceuticals which can be engaged to defeat the disease-initiating neurodegenerative insult, thereby introducing the possibility of preventing these devastating diseases. There are direct implications for the human cancers, but verification of those implications must await further experiments.

The first major activity under the Project’s second phase will be the production of a new class of active imaging system. That system will be utilized to demonstrate the activities and accessible control points of the process pathways which, when certain abnormal events occur, trigger the incipient causal mechanisms of disease. The Project is currently developing the staff and capitalization required for execution of its second phase.

About IDCC 
IDCC was founded thirteen years ago to produce definitive solutions to seemingly intractable problems of social and technological significance. It is privately held and maintains its projects and client identities in strict confidence unless and until information releases are authorized by competent authority.

Contact Details: Peter W. Atkinson
IDCC
4655 Logsdon Drive
Annandale, VA 22003-3564 USA
+1.703.879.7065
Peter@InterfaceDynamicsControl.com

Via EPR Network
More Healthcare press releases

Top Government Hospital for Stem Cell Treatments and Research Located in Beijing Launches English Website

The Stem Cell Transplantation Department at the General Hospital of Chinese People’s Armed Police Forces has launched an English version of its website www.sinostemcells.com for its ever-growing international patients seeking Stem cell treatments. The new user-friendly site reflects the department’s vision of readily available, authentic, and relevant information and aims to supply its online visitors with up-to-date information on the department’s current stem cell therapies and research programs.

The Stem Cell Transplantation Department Director Dr. Yihua An, PhD, says “Access to relevant, quality information is becoming more important for international patients, their physicians, and families. We have met the ever-increasing need for English language updates on our current research direction and practices and have developed a modern English website especially designed for a Western audience.”

The department is located at the General Hospital of Chinese People’s Armed Police Forces in Beijing – a top Level 3A military institution that integrates healthcare services, scientific research, and medical education.

The Stem cell department is active in the field of stem cell treatments and research. The department primary focus is on Stem cell treatment for Spinal Cord Injury and Brain Injury apart from central nervous system -related diseases like Cerebral palsy and Stroke.

Via EPR Network
More Healthcare press releases

The National Alliance on Mental Illness Launches Social Networking Site for Young Adults

The National Alliance on Mental Illness (NAMI) has launched StrengthofUs.org, a new online community where young adults living with mental health concerns can provide mutual support in navigating unique challenges and opportunities during the critical transition years from ages 18 to 25.

The National Alliance on Mental Illness Launches Social Networking Site for Young Adults

Developed by young adults, StrengthofUs.org is a user-driven social networking community where members can connect with peers, share personal stories, creativity and helpful resources by writing and responding to blog entries, engaging in discussion groups and sharing videos, photos and other news.

The site offers resources on issues important to young adults, including:

• Healthy relationships
• Family and friends
• Campus life
• Independent living
• Finances
• Employment
• Housing
• Mental health issues

“Young adulthood is an exciting challenge, but also a confusing and stressful time for anyone,” said Michael Fitzpatrick, NAMI executive director. “Life can throw things at you fast.”

“Mental illness affects everyone. StrengthofUs.org is intended not just for young adults who have a mental illness, but for anyone entering adulthood that has a friend, parent or other family member facing a mental health problem.”

“Most of all, StrengthofUs.org is an interactive, fun space where young adults can share experiences and other information to empower each other, build relationships and offer peer support.”

StrengthofUs.org is about helping and inspiring each other,” said Alex M. White, age 23, a member of the advisory group of young adults who helped develop the Web site. “I would not be alive today if it had not been for the love, care and support I received from family, friends and loved ones.”.

About NAMI
NAMI is the nation’s largest grassroots mental health organization dedicated to improving the lives of individuals and families affected by mental illness. NAMI has over 1100 state and local affiliates that engage in research, education, support and advocacy.

Via EPR Network
More
Healthcare press releases